FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

			of Section So(n) of the investment Company Act of 1940			
1	dress of Reporting	Person*	2. Issuer Name and Ticker or Trading Symbol Acadia Healthcare Company, Inc. [ACHC]		ationship of Reporting Po < all applicable)	erson(s) to Issuer
WAUD RE	<u>EVEB</u>		<u></u>	X	Director	10% Owner
	(First) CAPITAL PART LLE STREET,	(Middle) INERS, L.L.C.	3. Date of Earliest Transaction (Month/Day/Year) 07/05/2017		Officer (give title below)	Other (specify below)
		50112 4500	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Fili	ing (Check Applicable
(Street)				X	Form filed by One Re	eporting Person
CHICAGO	IL	60654			Form filed by More th Person	an One Reporting
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, Transaction		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock, par value \$0.01 per share	07/05/2017		S		50,000 ⁽¹⁾	D	\$50.043 ⁽²⁾	3,421,681 ⁽³⁾	Ι	See Footnotes ⁽⁴⁾⁽⁵⁾⁽⁶⁾
Common Stock, par value \$0.01 per share								6,110 ⁽⁷⁾	D	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b-5 plan adopted by the Halcyon Exempt Family Trust (the "Halcyon Trust") on March 17, 2017.

2. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions under Rule 144 at prices ranging from \$50.00 to \$50.17, inclusive. The reporting person undertakes to provide to Acadia Healthcare Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. The shares are owned of record as follows: (i) 428,032 shares by Waud Capital Partners II, L.P. ("WCP II"), (ii) 782,511 shares by Waud Capital Partners QP II, L.P. ("WCP QP II"), (iii) 119,425 by WCP FIF II (Acadia), L.P. ("WCP FIF II"), (iv) 122,311 shares by Waud Capital Affiliates II, L.L.C. ("Waud Affiliates II"), (v) 62,770 shares by Waud Capital Affiliates III, L.L.C. ("Waud Affiliates II"), (v) 62,770 shares by Waud Capital Affiliates III"), (vi) 170,501 shares by WCP FIF III (Acadia), L.P. ("WCP FIF III"), (vii) 388,500 shares by Waud Capital Partners QP III, L.P. ("WCP QP III"), (viii) 68,701 shares by Waud Capital Partners III, L.P. ("WCP III"), (viii) 381,113 shares by Waud Capital Partners, L.P. ("WCP III"), (vii) 333,333 shares by Melissa W. Waud, Mr. Waud's wife, (xii) 37,493 shares by WCP LLC and (xiii) 795,667 shares by Crystal Cove LP.

4. Waud Capital Partners Management II, L.P. ("WCPM II") is the general partner of WCP II, WCP QP II and WCP FIF II and the manager of Waud Affiliates II. Waud Capital Partners II, L.L.C. ("WCP II LLC") is the general partner of WCPM II. Waud Capital Partners Management III, L.P. ("WCPM III") is the general partner of WCP FIF III, WCP QP III and WCP FIF III, WCP QP III and WCP III and the Manager of Waud Affiliates III. Waud Capital Partners III, L.L.C. ("WCPM III") is the general partner of WCP FIF III, WCP QP III and WCP FIF III, WCP QP III and WCP III and the Manager of Waud Affiliates III. Waud Capital Partners III, L.L.C. ("WCPM III") is the general partner of WCPM III. Waud Capital Partners of WCPM III.

5. Mr. Waud may be deemed to beneficially own the shares of common stock reported herein by virtue of (A) his making decisions for the Limited Partner Committee of each of WCPM II and WCPM III, (B) his being the manager of WCP II LLC and WCP III LLC, (C) his being the general partner of WFP LP, (D) his being the investment advisor of the Halcyon Trust of which Mr. Waud's children are beneficiaries, (E) his being married to Ms. Waud, (F) his being the sole manager of WCP LLC and (G) his being the general partner of Crystal Cove LP.

6. Mr. Waud expressly disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

7. Represents shares held of record for the benefit of WCP LLC.

Remarks:

/s/ Reeve B. Waud

07/06/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.